EcoDrugPlus

Ribosomal Protein L28

Ensembl ID : ENSGEVG00005005745
Gene Symbol: RPL28
3 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L3

Ensembl ID : ENSGEVG00005001507
Gene Symbol: RPL3
2 Cross references
290 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35

Ensembl ID : ENSGEVG00005006381
Gene Symbol: RPL35
3 Cross references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L35a

Ensembl ID : ENSGEVG00005018766
Gene Symbol: RPL35A
1 Cross references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L36

Ensembl ID : ENSGEVG00005018205
Gene Symbol: RPL36
2 Cross references
393 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L39

Ensembl ID : ENSGEVG00005010742
Gene Symbol: RPL39
1 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L4

Ensembl ID : ENSGEVG00005005421
Gene Symbol: RPL4
3 Cross references
336 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L5

Ensembl ID : ENSGEVG00005004377
Gene Symbol: RPL5
3 Cross references
479 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L6

Ensembl ID : ENSGEVG00005019968
Gene Symbol: RPL6
3 Cross references
463 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L7

Ensembl ID : ENSGEVG00005002394
Gene Symbol: RPL7
2 Cross references
484 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L8

Ensembl ID : ENSGEVG00005004617
Gene Symbol: RPL8
3 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L9

Ensembl ID : ENSGEVG00005004712
Gene Symbol: RPL9
3 Cross references
505 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).